University of California Davis Comprehensive Cancer Center

Sacramento, CA

Sorting 4 by

Not yet accepting

CertainT-1

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)
Learn more
  • CER-T
  • TIM-4
  • Phase 1

Accepting patients

Orca-Q

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

Low Dose Weekly Decitabine/Venetoclax

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Learn more
  • Genetic Sequencing
  • Phase 2